Drug Profile
Research programme: influenza monoclonal antibodies - Kyowa Kirin
Latest Information Update: 16 Jul 2019
Price :
$50
*
At a glance
- Originator Kirin Brewery
- Developer Kyowa Hakko Kirin
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 01 Oct 2008 Kirin Pharma Company has merged with Kyowa Hakko to form Kyowa Hakko Kirin
- 02 Feb 2006 Data presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2005) have been added to the Viral infections pharmacodynamics section
- 26 Aug 2003 Discontinued - Preclinical for Autoimmune disorders in USA (Parenteral)